New combo therapy aims to shrink hard-to-treat stomach cancer before surgery

NCT ID NCT07072351

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for people with advanced gastroesophageal junction cancer that cannot be removed with surgery right away. The treatment combines targeted radiation, immunotherapy, and chemotherapy to shrink the tumor enough for surgery. The goal is to see if this combination is safe and effective, with 88 adults expected to take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA HYPOFRACTIONATED RADIOTHERAPY IMMUNOTHERAPY

Contacts and locations

Locations

The Seventh People's Hospital of Chengdu
RECRUITING

Chengdu, Sichuan, 610041, China
West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China
West China Shangjin Nanfu Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China
West China Xiamen Hospital, Sichuan University
RECRUITING

Xiamen, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.